Phase III Trial of Consolidation Therapy With Yttrium-90???Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma, Journal of Clinical Oncology, vol.26, issue.32, pp.5156-64, 2008. ,
DOI : 10.1200/JCO.2008.17.2015
Lu-Dotatate for Midgut Neuroendocrine Tumors, New England Journal of Medicine, vol.376, issue.2, pp.125-160, 2017. ,
DOI : 10.1056/NEJMoa1607427
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer, New England Journal of Medicine, vol.369, issue.3, pp.213-236, 2013. ,
DOI : 10.1056/NEJMoa1213755
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial, The Lancet Oncology, vol.15, issue.12, pp.1397-406, 2014. ,
DOI : 10.1016/S1470-2045(14)70474-7
Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations, Targeted Oncology, vol.46, issue.2, 2018. ,
DOI : 10.1053/j.semnuclmed.2015.10.012
Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study, European Journal of Nuclear Medicine and Molecular Imaging, vol.10, 2018. ,
DOI : 10.1371/journal.pone.0130249
Phase I trial of ?-particle therapy with actinium-225 (225Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML), J Clin Oncol, vol.33, issue.7050, 2015. ,
DOI : 10.1200/jco.2011.29.15_suppl.6516
225Ac-PSMA-617 for PSMA-Targeted ??-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer, Journal of Nuclear Medicine, vol.57, issue.12, pp.1941-1945, 2016. ,
DOI : 10.2967/jnumed.116.178673
URL : http://jnm.snmjournals.org/content/57/12/1941.full.pdf